<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477580</url>
  </required_header>
  <id_info>
    <org_study_id>V180-001</org_study_id>
    <nct_id>NCT01477580</nct_id>
  </id_info>
  <brief_title>Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)</brief_title>
  <official_title>A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether at least one formulation of an experimental dengue vaccine
      (V180) is safe and causes an immune response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate for each serotype</measure>
    <time_frame>28 days postdose 3 (Day 84)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) of virus neutralizing antibodies for each serotype</measure>
    <time_frame>28 days postdose 3 (Day 84)</time_frame>
  </primary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>Low-dose V180 with low-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose Non-adjuvanted V180</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-Dose V180 with Alhydrogel™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Non-adjuvanted V180</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose V180 with low-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose V180 with medium-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose V180 with high-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose V180 with high-dose ISCOMATRIX™ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-dose V180 with low-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Low-dose V180 with low-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium-dose V180 (non-adjuvanted)</intervention_name>
    <description>Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Medium-dose Non-adjuvanted V180</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium-dose V180 with Alhydrogel™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Medium-Dose V180 with Alhydrogel™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose V180 (non-adjuvanted)</intervention_name>
    <description>Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>High-dose Non-adjuvanted V180</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose V180 with low-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>High-dose V180 with low-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose V180 with medium-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>High-dose V180 with medium-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-dose V180 with high-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Low-dose V180 with high-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose V180 with high-dose ISCOMATRIX™ adjuvant</intervention_name>
    <description>Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2</description>
    <arm_group_label>High-dose V180 with high-dose ISCOMATRIX™ adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selected Inclusion Criteria:

          -  In good health

          -  Voluntarily agrees to participate by giving written informed consent

          -  Able to read, understand, and complete study questionnaires

          -  Able to complete all scheduled visits and comply with study procedures

          -  Access to a telephone

          -  Agrees to avoid unusual, vigorous exercise from 72 hours before any dose of study
             vaccine/placebo through 15 days after that dose

          -  Weighs ≥110 pounds (50 kg) and has a body mass index (BMI) of 19 to 32 kg/m^2

          -  No fever (temperature ≥100.4°F/38.0°C) for 72 hours prior to vaccination

          -  Females of reproductive potential agree to remain abstinent or to use 2 acceptable
             methods of birth control from enrollment through 6 weeks after the last dose of study
             vaccine/placebo

        Selected Exclusion Criteria:

          -  History of receiving any flavivirus vaccine (e.g. Japanese encephalitis, tick-borne
             encephalitis, or yellow fever) or planned receipt of any such vaccine during the study
             period

          -  History of any flavivirus infection or serologic evidence of any flavivirus infection,
             including West Nile, dengue, yellow fever, Saint Louis encephalitis (if available),
             Kunjin, Murray Valley encephalitis, and Japanese encephalitis

          -  History of residence for a cumulative period of &gt;1 year in a country where dengue,
             Japanese encephalitis virus, or yellow fever virus is common

          -  Planned travel to an area where dengue is common through 28 days after receiving the
             last dose of study vaccine/placebo

          -  Known hypersensitivity to any component of the dengue vaccine

          -  Abuse of drugs or alcohol within 12 months prior to screening

          -  Pregnant or breastfeeding, or expecting to conceive in the time from enrollment
             through 6 weeks after the last dose of study vaccine/placebo

          -  Positive serum test for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), and/or hepatitis C antibody

          -  Known, suspected, or a history of immunocompromise

          -  History of malignancy within 5 years prior to enrollment

          -  Poorly controlled diabetes mellitus

          -  Use of any immunosuppressive therapy (except topical and inhaled/nebulized steroids)

          -  Receipt of any licensed non-live vaccine within 14 days prior to the first dose of
             study vaccine/placebo or plans to receive a licensed non-live vaccine during the time
             between receiving the first dose and 28 days after receiving the last dose of study
             vaccine/placebo

          -  Receipt of any licensed live vaccine within 30 days prior to the first dose of study
             vaccine/placebo or plans to receive a licensed live vaccine during the time between
             receiving the first dose and 28 after receiving the last dose of study vaccine/placebo

          -  Received investigational drugs or vaccines within 2 months prior to the first dose of
             study vaccine/placebo

          -  History of receiving 1 or more doses of an investigational dengue vaccine

          -  Participation in another clinical study within 42 days prior to enrollment, or plans
             to participate in another clinical study from enrollment through 1 year after the last
             dose of study vaccine/placebo

          -  Planned donation of eggs or sperm from the time of enrollment through 28 days after
             the last dose of study vaccine/placebo

          -  Prior receipt of a blood transfusion or blood products within 6 months prior to the
             first dose of study vaccine/placebo

          -  Hospitalization for acute illness within 3 months prior to the first dose of
             vaccine/placebo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <results_reference>
    <citation>Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA. Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine. 2015 Dec 10;33(50):7126-34. doi: 10.1016/j.vaccine.2015.09.101. Epub 2015 Oct 14. Review.</citation>
    <PMID>26458804</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

